Search

The Seveso III Directive 2012/18/EU imposes an obligation to take into due consideration the human factors and the interfaces between operators, processes, and plants, as part of the implementation of the Safety Management System. The national technical standard UNI 10616:2022 provides guidelines for implementing a safety management system, describing the procedures and technical tools useful for achieving specific objectives for the prevention of major accidents. In the standard, specific attention is paid to the human-machine interface (HMI). In close connection, it is considered the prevention and assessment of human error, a fundamental aspect of process safety management. A good, designed man-machine interface, in the control room of a process plant, allows you to minimize the possibility of operator error on the panel. The assessment of the possibility of human error must be used in the reliability analysis to verify if the procedures and operational controls adopted to improve the behavior of the operator or the instrumental controls give the best contribution to the safety of the system, preparing any corrective actions, also in terms of response times and emergency management of the operators, to reduce the possibility of accidents. The consideration of the human factors and the interfaces between operators, processes, and plants, in the correct implementation of a safety management system must be finally based on the functionality of the operator/process and operator/equipment interfaces to monitor the process, identify any anomalies or emergencies, and implement the planned intervention procedures. [ABSTRACT FROM AUTHOR]

Copyright of Summa, Animali da Reddito is the property of Point Veterinaire Italie s.r.l. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Summa, Animali da Compagnia is the property of Point Veterinaire Italie s.r.l. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Summa, Animali da Compagnia is the property of Point Veterinaire Italie s.r.l. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Summa, Animali da Compagnia is the property of Point Veterinaire Italie s.r.l. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Simple Summary: Radiomics analysis is used on magnetic resonance imaging – apparent diffusion coefficient (MRI-ADC) maps and [68Ga]Ga-PSMA-11 PET uptake maps to assess unique tumor traits not visible to the naked eye and predict histology-proven ISUP grades in a cohort of 28 patients. Our study's main goal is to report imaging features that can distinguish patients with low ISUP grades from those with higher grades (ISUP one+) by employing logistic regression statistical models based on MRI-ADC and 68Ga-PSMA data, as well as assess the features' stability under small contouring variations. Our findings reveal that MRI-ADC and [68Ga]Ga-PSMA-11 PET imaging features-based models are equivalent and complementary for predicting low ISUP grade patients. These models can be employed in broader studies to confirm their ISUP grade prediction ability and eventually impact clinical workflow by reducing overdiagnosis of indolent, early-stage PCa. Prostate cancer (PCa) risk categorization based on clinical/PSA testing results in a substantial number of men being overdiagnosed with indolent, early-stage PCa. Clinically non-significant PCa is characterized as the presence of ISUP grade one, where PCa is found in no more than two prostate biopsy cores.MRI-ADC and [68Ga]Ga-PSMA-11 PET have been proposed as tools to predict ISUP grade one patients and consequently reduce overdiagnosis. In this study, Radiomics analysis is applied to MRI-ADC and [68Ga]Ga-PSMA-11 PET maps to quantify tumor characteristics and predict histology-proven ISUP grades. ICC was applied with a threshold of 0.6 to assess the features' stability with variations in contouring. Logistic regression predictive models based on imaging features were trained on 31 lesions to differentiate ISUP grade one patients from ISUP two+ patients. The best model based on [68Ga]Ga-PSMA-11 PET returned a prediction efficiency of 95% in the training phase and 100% in the test phase whereas the best model based on MRI-ADC had an efficiency of 100% in both phases. Employing both imaging modalities, prediction efficiency was 100% in the training phase and 93% in the test phase. Although our patient cohort was small, it was possible to assess that both imaging modalities add information to the prediction models and show promising results for further investigations. [ABSTRACT FROM AUTHOR]

Cancer is a risk factor for venous thromboembolism (VTE). Plasma tumor DNA (ptDNA) is an independent predictor of outcome in metastatic castration‐resistant prostate cancer (mCRPC). We aimed to investigate the association between ptDNA and VTE in mCRPC. This prospective biomarker study included 180 mCRPC patients treated with abiraterone and enzalutamide from April 2013 to December 2018. We excluded patients with a previous VTE history and/or ongoing anticoagulation therapy. Targeted next‐generation sequencing was performed to determine ptDNA fraction from pretreatment plasma samples. VTE risk based on survival analysis was performed using cumulative incidence function and estimating sub‐distributional hazard ratio (SHR). At a median follow‐up of 58 months (range 0.5‐111.0), we observed 21 patients who experienced VTE with a cumulative incidence at 12 months of 17.1% (95% confidence interval [CI] 10.3‐23.9). Elevated ptDNA, visceral metastasis, prior chemotherapy and lactate dehydrogenase (LDH) were significantly associated with higher VTE incidence compared to patients with no thrombosis (12‐month estimate, 18.6% vs 3.5%, P =.0003; 44.4% vs 14.8%, P =.015; 24.7% vs 4.5%, P =.006; and 30.0% vs 13.5%, P =.05, respectively). In the multivariate analysis including ptDNA level, visceral metastases, number of lesions and serum LDH, high ptDNA fraction was the only independent factor associated with the risk of thrombosis (HR 5.78, 95% CI 1.63‐20.44, P =.006). These results first suggest that baseline ptDNA fraction in mCRPC patients treated with abiraterone or enzalutamide may be associated with increased VTE risk. These patients may be followed‐up more closely for the VTE risk, and the need for a primary thromboprophylaxis should be taken into account in mCRPC with elevated ptDNA. What's new? Patients with cancer are at increased risk for venous thromboembolism (VTE). Here, the authors test the correlation between plasma tumor DNA (ptDNA) and VTE in patients with metastatic castration‐resistant prostate cancer. In prostate cancer, the concentration of ptDNA prior to treatment can predict clinical outcome. This study enrolled 180 patients who were receiving androgen deprivation therapy. The patients with high ptDNA had a greater incidence of VTE than those with low ptDNA. These results suggest that ptDNA could be a useful tool for assessing VTE risk and improving long‐term survival. [ABSTRACT FROM AUTHOR]

The possibility that magnetic fields (MFs) induce anticancer activity in vivo has been investigated by using a highly metastatic human cancer model transplanted in immunoincompetent mice (CD-1, nu-nu). The nude mice, bearing a subcutaneous human breast tumor (MDA-MB-435), were exposed for 70 min daily, for six consecutive weeks, to modulated MF (static with a superimposition of extremely low-frequency fields at 50 Hz) having a time-average total intensity of 5.5 mT. A positive control group was treated with a chemotherapeutic agent (cyclophosphamide). Neither MF nor cyclophosphamide significantly reduced the total number of pulmonary metastases. Both treatments induced a significant inhibition on spread and growth of intermediate (10-100 cells) and large (>100 cells) lung metastases compared with the MF sham-treatment. The inhibition induced by the MF was significantly greater than that observed in mice treated with cyciophosphamide. Gross pathology at necroscopy, hematoclinical/ hematological, and histological examination did not show any toxic or abnormal effects. These findings support a potential use of MF as an anticancer agent. Index Terms--Anticancer activity, breast cancer, magnetic fields, metastasis, MDA-MB-435.

Copyright of Summa, Animali da Compagnia is the property of Point Veterinaire Italie s.r.l. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Summa, Animali da Compagnia is the property of Point Veterinaire Italie s.r.l. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Summa, Animali da Compagnia is the property of Point Veterinaire Italie s.r.l. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Summa, Animali da Compagnia is the property of Point Veterinaire Italie s.r.l. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)